IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer

Oncotarget

Volumn 6, Issue 32, 2015, Pages 32966-32979

  Chen, Xiaowei ^a,b   Churchill, Michael J ^a   Nagar, Karan K ^a   Tailor, Yagnesh H ^a   Chu, Timothy ^a   Rush, Brittany S ^a   Jiang, Zhengyu ^a   Wang, Edwin B C ^a   Renz, Bernhard W ^a   Wang, Hongshan ^a   Fung, Ming Chiu ^b   Worthley, Daniel L ^a   Mukherjee, Siddhartha ^a   Wang, Timothy C ^a  

^a Columbia University ^*  (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Colorectal cancer; Histamine deficiency; IL 17; Mast cell; Myeloid derived suppressor cell

Indexed keywords

ARGINASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 17; OVALBUMIN; HISTAMINE; OVA 323-339; PEPTIDE FRAGMENT;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL EXPANSION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FOOD ALLERGY; HUMAN; MAST CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; TH2 CELL; TUMOR CELL INOCULATION; TUMOR GROWTH; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; COLORECTAL TUMOR; DISEASE MODEL; HYPERSENSITIVITY; IMMUNOLOGY; KNOCKOUT MOUSE; MOLECULAR GENETICS; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE; HYPERSENSITIVITY; INTERLEUKIN-17; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MYELOID CELLS; OVALBUMIN; PEPTIDE FRAGMENTS;

EID: 84946082735     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5435     Document Type: Article

References (61)

1. Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. European journal of immunology. 2010; 40:1843-1851.
2. Liu J, Zhang Y, Zhao J, Yang Z, Li D, Katirai F, Huang B. Mast cell: insight into remodeling a tumor microenvironment. Cancer and Metastasis Reviews. 2011; 30:177-184.
3. Tanaka T, Ishikawa H. Mast cells and inflammationassociated colorectal carcinogenesis. Semin Immunopathol. 2013; 35:245-254.
4. Mazzoni A, Siraganian RP, Leifer CA, Segal DM. Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol. 2006; 177:3577-3581.
5. Dudeck A, Suender CA, Kostka SL, von Stebut E, Maurer M. Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol. 2011; 41:1883-1893.
6. Blatner NR, Bonertz A, Beckhove P, Cheon EC, Krantz SB, Strouch M, Weitz J, Koch M, Halverson AL, Bentrem DJ, Khazaie K. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:6430-6435.
7. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H. Differential responses of mast cell Tolllike receptors 2 and 4 in allergy and innate immunity. J Clin Invest. 2002; 109:1351-1359.
8. Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH. Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol. 2012; 189:511-515.
9. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, Villanueva EC, Shah P, Kaplan MJ, Bruce AT. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011; 187:490-500.
10. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nature reviews Immunology. 2012; 12:253-268.
11. Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GK, Ryan JJ, Bear HD, Irani AM, Conrad DH. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J Leukoc Biol. 2014; 96:151-159.
12. Danelli L, Frossi B, Gri G, Mion F, Guarnotta C, Bongiovanni L, Tripodo C, Mariuzzi L, Marzinotto S, Rigoni A, Blank U, Colombo MP, Pucillo CE. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer immunology research. 2015; 3:85-95.
13. Hsu CL, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010; 5:e11944.
14. Heger K, Fierens K, Vahl JC, Aszodi A, Peschke K, Schenten D, Hammad H, Beyaert R, Saur D, van Loo G, Roers A, Lambrecht BN, Kool M, Schmidt-Supprian M. A20-deficient mast cells exacerbate inflammatory responses in vivo. PLoS Biol. 2014; 12:e1001762.
15. Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nature reviews Rheumatology. 2013; 9:375-379.
16. De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, Gunzer M, Roers A, Hogg N. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013; 121:4930-4937.
17. Kim HY, Lee HJ, Chang YJ, Pichavant M, Shore SA, Fitzgerald KA, Iwakura Y, Israel E, Bolger K, Faul J, DekruyffRH, Umetsu DT. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014; 20:54-61.
18. Li L, Huang L, Vergis AL, Ye H, Bajwa A, Narayan V, Strieter RM, Rosin DL, Okusa MD. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest. 2010; 120:331-342.
19. Kim JS, Jordan MS. Diversity of IL-17-producing T lymphocytes. Cell Mol Life Sci. 2013; 70:2271-2290.
20. Jones SA, Sutton CE, Cua D, Mills KH. Therapeutic potential of targeting IL-17. Nat Immunol. 2012; 13:1022-1025.
21. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012; 122:487-511.
22. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica. 2012; 97:599-607.
23. Wang B, Li L, Liao Y, Li J, Yu X, Zhang Y, Xu J, Rao H, Chen S, Zhang L, Zheng L. Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2013; 62:1575-1585.
24. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nature medicine. 2013; 19:1114-1123.
25. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009; 119:3011-3023.
26. Wood JD. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. Gut. 2006; 55:445-447.
27. Xie H, He SH. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. World J Gastroenterol. 2005; 11:2851-2857.
28. Yang XD, Ai W, Asfaha S, Bhagat G, Friedman RA, Jin G, Park H, Shykind B, Diacovo TG, Falus A, Wang TC. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med. 2011; 17:87-95.
29. Merrill RM, Isakson RT, Beck RE. The association between allergies and cancer: what is currently known? Ann Allergy Asthma Immunol. 2007; 99:102-116. quiz 117-109, 150.
30. Engkilde K, Thyssen JP, Menne T, Johansen JD. Association between cancer and contact allergy: a linkage study. BMJ open. 2011; 1:e000084.
31. Smolinska S, Jutel M, Crameri R, O'Mahony L. Histamine and gut mucosal immune regulation. Allergy. 2014; 69:273-281.
32. Santos J, Bayarri C, Saperas E, Nogueiras C, Antolin M, Mourelle M, Cadahia A, Malagelada JR. Characterisation of immune mediator release during the immediate response to segmental mucosal challenge in the jejunum of patients with food allergy. Gut. 1999; 45:553-558.
33. Wiener Z, Buzas E, Kovacs P, Csaba G, Szabo D, Kittel A, Pallinger E, Watanabe T, Ohtsu H, Ichikawa A, Nagy A, Falus A. Highly reduced peritoneal mast cell number and decreased c-kit expression in histidine decarboxylase knock out mice. Inflamm Res. 2001; 50:S55-56.
34. Mirzahosseini A, Dalmadi B, Csutora P. Histamine receptor H4 regulates mast cell degranulation and IgE induced FcepsilonRI upregulation in murine bone marrow-derived mast cells. Cell Immunol. 2013; 283:38-44.
35. Cheon EC, Khazaie K, Khan MW, Strouch MJ, Krantz SB, Phillips J, Blatner NR, Hix LM, Zhang M, Dennis KL, Salabat MR, Heiferman M, Grippo PJ, Munshi HG, Gounaris E, Bentrem DJ. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res. 2011; 71:1627-1636.
36. Yang PC, Xing Z, Berin CM, Soderholm JD, Feng BS, Wu L, Yeh C. TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigen-specific Th2 differentiation and intestinal allergy. Gastroenterology. 2007; 133:1522-1533.
37. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol. 2001; 166:2173-2177.
38. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003; 170:270-278.
39. Saligrama N, Case LK, Krementsov DN, Teuscher C. Histamine H(2) receptor signaling x environment interactions determine susceptibility to experimental allergic encephalomyelitis. FASEB J. 2014; 28:1898-1909.
40. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol. 2006; 176:7062-7070.
41. Noubade R, Milligan G, Zachary JF, Blankenhorn EP, del Rio R, Rincon M, Teuscher C. Histamine receptor H1 is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J Clin Invest. 2007; 117:3507-3518.
42. Ohtsu H, Tanaka S, Terui T, Hori Y, Makabe-Kobayashi Y, Pejler G, Tchougounova E, Hellman L, Gertsenstein M, Hirasawa N, Sakurai E, Buzas E, Kovacs P, Csaba G, Kittel A, Okada M, et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett. 2001; 502:53-56.
43. Wiener Z, Andrasfalvy M, Pallinger E, Kovacs P, Szalai C, Erdei A, Toth S, Nagy A, Falus A. Bone marrow-derived mast cell differentiation is strongly reduced in histidine decarboxylase knockout, histamine-free mice. Int Immunol. 2002; 14:381-387.
44. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, Strom TB, Zheng XX, Noelle RJ. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006; 442:997-1002.
45. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX, Huang B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One. 2010; 5:e8922.
46. Nakazawa S, Sakanaka M, Furuta K, Natsuhara M, Takano H, Tsuchiya S, Okuno Y, Ohtsu H, Nishibori M, Thurmond RL, Hirasawa N, Nakayama K, Ichikawa A, Sugimoto Y, Tanaka S. Histamine synthesis is required for granule maturation in murine mast cells. Eur J Immunol. 2014; 44:204-214.
47. Zhao Y, Balato A, Fishelevich R, Chapoval A, Mann DL, Gaspari AA. Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis. Br J Dermatol. 2009; 161:1301-1306.
48. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012; 491:254-258.
49. Ericksen RE, Rose S, Westphalen CB, Shibata W, Muthupalani S, Tailor Y, Friedman RA, Han W, Fox JG, Ferrante AW Jr., Wang TC. Obesity accelerates Helicobacter felis-induced gastric carcinogenesis by enhancing immature myeloid cell trafficking and TH17 response. Gut. 2014; 63:385-394.
50. Yazawa T, Shibata M, Gonda K, Machida T, Suzuki S, Kenjo A, Nakamura I, Tsuchiya T, Koyama Y, Sakurai K, Shimura T, Tomita R, Ohto H, Gotoh M, Takenoshita S. Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Molecular and clinical oncology. 2013; 1:675-679.
51. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nature reviews Immunology. 2010; 10:479-489.
52. Wu D, Wu P, Huang Q, Liu Y, Ye J, Huang J. Interleukin-17: a promoter in colorectal cancer progression. Clinical & developmental immunology. 2013; 2013:436307.
53. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, Chen Z, Wang K, Zhang T, Xu J, Han Y, Zhang T, et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014; 40:785-800.
54. Wu X, Zou Y, He X, Yuan R, Chen Y, Lan N, Lian L, Wang F, Fan X, Zeng Y, Ke J, Wu X, Lan P. Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. International journal of surgical pathology. 2013; 21:111-120.
55. Malfettone A, Silvestris N, Saponaro C, Ranieri G, Russo A, Caruso S, Popescu O, Simone G, Paradiso A, Mangia A. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. Journal of cellular and molecular medicine. 2013; 17:1025-1037.
56. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthmatic patients. International journal of epidemiology. 1993; 22:976-982.
57. Prizment AE, Folsom AR, Cerhan JR, Flood A, Ross JA, Anderson KE. History of allergy and reduced incidence of colorectal cancer, Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2007; 16:2357-2362.
58. Rittmeyer D, Lorentz A. Relationship between Allergy and Cancer: An Overview. International Archives of Allergy and Immunology. 2012; 159:216-225.
59. Shadman M, White E, De Roos AJ, Walter RB. Associations between allergies and risk of hematologic malignancies: Results from the VITamins and lifestyle cohort study. American Journal of Hematology. 2013; 88:1050-1054.
60. Wang H, Diepgen TL. Atopic dermatitis and cancer risk. Br J Dermatol. 2006; 154:205-210.
61. Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature. 2012; 484:465-472.